← 返回

CAR-T 后患者经延长静脉瑞德西韦与疫苗接种清除持续性 SARS-CoV-2 感染

英文原题:Resolution of persistent SARS-CoV-2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR-T.

查看英文原题

Resolution of persistent SARS-CoV-2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR-T.

PubMed 2023/02/09(内容时间) Int J Hematol Q3 · IF 1.9(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

SARS-CoV-2病毒是一种单链包膜RNA病毒,可导致冠状病毒病。多数免疫功能正常的SARS-CoV-2感染者仅出现轻至中度呼吸道疾病;但免疫功能低下患者的感染病程不可预测,感染性和死亡率均高。因此,早期识别免疫功能低下患者并据此制定治疗方案十分重要。本文介绍一例25岁男性患者,其病史包括B细胞急性淋巴细胞白血病、骨髓移植后状态及CAR-T 细胞治疗。患者接受瑞德西韦治疗并接种疫苗;从症状出现至接种疫苗后共随访6个月,患者症状消退,免疫学指标改善。本文还回顾旨在使该患者实现治愈的SARS-CoV-2感染病程和治疗相关文献。

展开英文摘要原文

SARS-CoV-2 virus is a single-stranded enveloped RNA virus, which causes coronavirus disease. Most of the immunocompetent patients with SARS-CoV-2 infection do have mild to moderate respiratory illness; however, in immunocompromised patients, the course of infection is unpredictable with high rates of infectivity and mortality. So, it is important to identify the immunocompromised patients early and establish the course of treatment accordingly.

Here, we describe a 25-year-old male with background of B cell ALL, post-BMT and CAR-T therapy who received treatment with remdesivir and vaccination and was followed up for six months from the onset of symptoms to post vaccination, which showed resolution of symptoms and improvement of immunological markers.

Here, we review the literature concerning the course and treatment of SARS-CoV-2 infection aimed at achieving cure in this patient.

论文信息

作者
Ambati S、Ali B、Seddon O、Godkin A、Scurr M、Moore C、Rowntree C、Underwood J
单位
Department of Internal Medicine, Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff, Wales, UK. Sai.ambati@wales.nhs.uk.United Kingdom
文献类型
病例报告 · 综述
期刊
International journal of hematology2023 May
原文标识
PubMed 36757522 · DOI 10.1007/s12185-022-03518-2